Olayinka Okeleji

8PUBLICATIONS
14CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 08, 2026
Resolution of Neuroblastoma-Related Opsoclonus-Myoclonus Ataxia Syndrome Following Tandem High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation and Extensive Intravenous Immunoglobulin.

|Mar 27, 2026
Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors.

Maria Frost, Olayinka Okeleji, Amr Elgehiny

|Dec 08, 2025
Navigating Management of Spindle Cell/Sclerosing Rhabdomyosarcoma With FUS::TFCP2 Fusion in the Era of Targeted Therapy.

Olayinka Okeleji, Reeja Raj, Sherani Farha

|Oct 03, 2025
Synchronous Mediastinal Germ Cell Tumor with Sarcomatous Transformation and Acute Myeloid Leukemia.

Elysia Cohen, Olayinka Okeleji, David McCall

|May 20, 2025
Allogeneic Hematopoietic Stem Cell Transplant for an Unknown Inherited Bone Marrow Failure Syndrome With a Novel Compound Heterozygous Mutation.

Olayinka Okeleji, Sajad Khazal, Kris M Mahadeo

|Feb 24, 2025
Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia.

Olayinka Okeleji, David McCall, Amber Gibson

Pageof 2

Frequent Collaborators

4 joint publications

David McCall

4 joint publications

Irtiza N Sheikh

3 joint publications

Amber Gibson

3 joint publications

Miriam Garcia